The fixed combination of the drugs tafluprost and timolol (trade name: Taptiqom) has been approved in Germany since December 2014 for adults with open-angle glaucoma or increased intraocular pressure (ocular hypertension). The combination therapy is indicated in patients who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues, and who would benefit from preservative-free eye drops.

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug combination offers an added benefit over the appropriate comparator therapy. However, such an added benefit cannot be derived from the dossier, as the study results are very uncertain and evaluable data on important outcomes are lacking.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/open-angle-glaucoma-poor-data-for-the-fixed-combination-tafluprost/timolol.6631.html